Jianyong Lei1, Wentao Wang, Lunan Yan. 1. Liver Transplantation Center, West China Hospital of Sichuan University, Chengdu, 610041, China. leijianyong11@163.com
Abstract
BACKGROUND AND AIMS: Many hepatocellular carcinoma (HCC) patients met the appropriate criteria and accepted liver transplantation after successful downstaging therapies; however, the outcome in these patients is unclear. We aim to compare the outcome of patients meeting the Milan criteria at the beginning and after successful downstaging therapies. PATIENTS AND METHODS: Between July 2001 and January 2013, 112 patients were diagnosed with early-stage HCC that met the Milan criteria. Of these patients, 58 patients did not meet the Milan criteria initially but did after successful downstaging therapies. We retrospectively collected and then compared the baseline characteristics, postoperative complications, survival rate, and tumor recurrence rate of these two groups. Kaplan-Meier analyses were used to estimate the long-term overall survival and tumor-free survival in these patients. RESULTS: No significant differences were observed between the two groups with respect to baseline donor and recipient characteristics. The downstaging Milan group showed similar tumor characteristics compared to the conventional Milan group, except the downstaging group had better tumor histopathologic grading (P = 0.027). The 1-, 3-, and 5-year overall survival rates were comparable at 91.4, 82.8, and 70.7 %, respectively, in the downstaging Milan criteria and 92.0, 85.7, and 74.1 %, respectively, according to the initial Milan criteria (P = 0.540). The 1-, 3-, and 5-year tumor-free survival rates between the two groups were not statistically significant (P = 0.667). CONCLUSION: Successful downstaging therapies can provide a comparable posttransplantation overall survival and tumor-free survival rates after liver transplantation.
BACKGROUND AND AIMS: Many hepatocellular carcinoma (HCC) patients met the appropriate criteria and accepted liver transplantation after successful downstaging therapies; however, the outcome in these patients is unclear. We aim to compare the outcome of patients meeting the Milan criteria at the beginning and after successful downstaging therapies. PATIENTS AND METHODS: Between July 2001 and January 2013, 112 patients were diagnosed with early-stage HCC that met the Milan criteria. Of these patients, 58 patients did not meet the Milan criteria initially but did after successful downstaging therapies. We retrospectively collected and then compared the baseline characteristics, postoperative complications, survival rate, and tumor recurrence rate of these two groups. Kaplan-Meier analyses were used to estimate the long-term overall survival and tumor-free survival in these patients. RESULTS: No significant differences were observed between the two groups with respect to baseline donor and recipient characteristics. The downstaging Milan group showed similar tumor characteristics compared to the conventional Milan group, except the downstaging group had better tumor histopathologic grading (P = 0.027). The 1-, 3-, and 5-year overall survival rates were comparable at 91.4, 82.8, and 70.7 %, respectively, in the downstaging Milan criteria and 92.0, 85.7, and 74.1 %, respectively, according to the initial Milan criteria (P = 0.540). The 1-, 3-, and 5-year tumor-free survival rates between the two groups were not statistically significant (P = 0.667). CONCLUSION: Successful downstaging therapies can provide a comparable posttransplantation overall survival and tumor-free survival rates after liver transplantation.
Authors: U Cillo; A Vitale; F Grigoletto; E Gringeri; F D'Amico; M Valmasoni; A Brolese; G Zanus; N Srsen; A Carraro; P Burra; F Farinati; P Angeli; D F D'Amico Journal: Am J Transplant Date: 2007-04 Impact factor: 8.086
Authors: Gerd Otto; Sascha Herber; Michael Heise; Ansgar W Lohse; Christian Mönch; Fernando Bittinger; Maria Hoppe-Lotichius; Marcus Schuchmann; Anja Victor; Michael Pitton Journal: Liver Transpl Date: 2006-08 Impact factor: 5.799
Authors: F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts Journal: Hepatology Date: 2001-06 Impact factor: 17.425
Authors: Omar Barakat; R Patrick Wood; Claire F Ozaki; Victor Ankoma-Sey; Joseph Galati; Mark Skolkin; Barry Toombs; Mary Round; Warren Moore; Luis Mieles Journal: Liver Transpl Date: 2010-03 Impact factor: 5.799
Authors: Francis Y Yao; Robert K Kerlan; Ryutaro Hirose; Timothy J Davern; Nathan M Bass; Sandy Feng; Marion Peters; Norah Terrault; Chris E Freise; Nancy L Ascher; John P Roberts Journal: Hepatology Date: 2008-09 Impact factor: 17.425
Authors: William C Chapman; M B Majella Doyle; Jourdan E Stuart; Neeta Vachharajani; Jeffrey S Crippin; Christopher D Anderson; Jeffrey A Lowell; Surendra Shenoy; Michael D Darcy; Daniel B Brown Journal: Ann Surg Date: 2008-10 Impact factor: 12.969
Authors: Giuseppe Maria Ettorre; Giovanni Battista Levi Sandri; Andrea Laurenzi; Marco Colasanti; Roberto Luca Meniconi; Raffaella Lionetti; Roberto Santoro; Pasquale Lepiane; Rosa Sciuto; Giuseppe Pizzi; Roberto Cianni; Rita Golfieri; Gianpiero D'Offizi; Adriano M Pellicelli; Mario Antonini; Giovanni Vennarecci Journal: World J Surg Date: 2017-01 Impact factor: 3.352
Authors: Giovanni Battista Levi Sandri; Giuseppe Maria Ettorre; Valerio Giannelli; Marco Colasanti; Rosa Sciuto; Giuseppe Pizzi; Roberto Cianni; Gianpiero D'Offizi; Mario Antonini; Giovanni Vennarecci; Pierleone Lucatelli Journal: Transl Gastroenterol Hepatol Date: 2017-11-27
Authors: L Jiang; J Y Lei; W T Wang; L N Yan; B Li; T F Wen; M Q Xu; J Y Yang; Y G Wei Journal: J Gastrointest Surg Date: 2014-03-25 Impact factor: 3.452
Authors: Dai Hoon Han; Dong Jin Joo; Myoung Soo Kim; Gi Hong Choi; Jin Sub Choi; Young Nyun Park; Jinsil Seong; Kwang Hyub Han; Soon Il Kim Journal: Yonsei Med J Date: 2016-09 Impact factor: 2.759